Back to top

Image: Bigstock

Sallie Mae (SLM) Q3 Earnings Beat Estimates, Provisions Fall

Read MoreHide Full Article

Sallie Mae (SLM - Free Report) reported third-quarter 2020 earnings per share of 47 cents (on core basis) beating the Zacks Consensus Estimate of 14 cents. Also, the bottom line compared favorably with 29 cents reported in the prior-year quarter.

Results benefited from the company’s prudent cost management and improved loans balance. Also, benefit from loan losses was a tailwind. However, lower revenues posed a major undermining factor.

The company’s GAAP net income attributable to common stock was $169 million or 45 cents compared with $124.3 million or 29 cents a year ago.

Net Interest Income Declines, Expenses Fall

Net interest income for the third quarter was $364.6 million, down 10% year over year. The decline is attributable to lower interest income. Net interest margin contracted to 4.79% in the quarter from 5.55% reported in the year-ago quarter.

The company’s non-interest income was $9.6 million compared with $17.2 million in the prior-year quarter. The decline mainly stemmed from lower other income and loss on derivatives and hedging activities.

The company’s non-interest expenses fell 1.3% year over year to $151.6 million. The fall mainly resulted from lower FDIC assessment fees, partly offset by higher restructuring expenses.

Credit Quality: A Mixed Bag

The company recorded a benefit from loan losses of $3.6 million against expenses of $99.5 million witnessed in the prior-year quarter.

Delinquencies as a percentage of private education loans in repayment were 3%, up 2 basis points from the year-ago quarter.

Loans Rise, Deposits Decline

As of Sep 30, 2020, deposits of Sallie Mae were $23.1 billion, down marginally from $23.6 billion as of Jun 30, 2020. Lower brokered deposits contributed to the downside.

Loans held for investment were $21.7 billion as of Sep 30, 2020, up 2.4% sequentially. Private education loan portfolio (97% of total loans) was $21 billion, up 5.9% on a sequential basis. During the quarter, the company witnessed private education loan originations of $1.9 billion.

Capital Position Strong

As of Sep 30, 2020, Sallie Mae’s common equity Tier 1 capital was 12.7%, exceeding the “well-capitalized” industry benchmark in regulatory requirements.

Our Viewpoint

Sallie Mae remains focused on increasing private education loan assets, maintaining a solid capital position by introducing multiple complementary products and improving efficiency. Additionally, its aim to solidify presence in the consumer banking business space bodes well. However, the contraction of margin due to lower rates and falling fee income keep the top line under pressure.

SLM Corporation Price, Consensus and EPS Surprise

SLM Corporation Price, Consensus and EPS Surprise

SLM Corporation price-consensus-eps-surprise-chart | SLM Corporation Quote

 

Currently, Sallie Mae carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other Companies

Navient Corporation (NAVI - Free Report) reported third-quarter 2020 core earnings per share of 99 cents that surpassed the Zacks Consensus Estimate of 78 cents. Also, the bottom line was above the year-ago quarter figure of 62 cents.

Riding on solid mortgage banking, Synovus Financial (SNV - Free Report) reported third-quarter 2020 adjusted earnings of 89 cents per share, handily beating the Zacks Consensus Estimate of 48 cents. However, the reported figure comes in 8.7% lower than the prior-year quarter tally.

Northern Trust (NTRS - Free Report) delivered third-quarter 2020 earnings per share of $1.32, missing the Zacks Consensus Estimate of $1.40, on lower revenues. Also, the reported figure declined 21.9% year over year. Results included certain one-time items.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>